Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
ObjectiveIn the double-blind, phase III, placebo-controlled RUBY randomized clinical trial, dostarlimab plus carboplatin-paclitaxel significantly increased survival among patients with primary advanced or recurrent endometrial cancer (EC). We conducted a cost-effectiveness analysis of dostarlimab in...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Frontiers Media S.A.
2024-06-01
|
| Serija: | Frontiers in Pharmacology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1391896/full |